SciBX's second annual comprehensive analysis of
public-private partnerships and early stage venture financing activity reveals
that government institutions and organizations are taking a significant role in
forming and funding partnerships, and California-based companies are leading
the way in public-private partnership activity. On the financing front, biotech
startups in the San Francisco Bay Area took in the lion's share of early stage
venture dollars despite a year-over-year decline in worldwide early stage
venture investments in biotechs.
The 2012 U.S. regional data also highlight California's
strong showing in both PPP activity and early stage venture financing (see
"Further regional breakdown
of public-private partnerships").
Regional data out of Europe showed that the U.K. was
again the leader in PPP activity in 2012. U.K.-based companies signed on with
49 PPPs, and U.K.-based institutions were involved in 43 (see Figure 3.II).
Lou, K.-J. SciBX 6(5); doi:10.1038/scibx.2013.105
Published online Feb. 7, 2013
1. Cain, C. BioCentury 20(23),
A1-A4; June 4, 2012
2. Haas, M.J. SciBX 5(25);
3. Lou, K.-J. SciBX 5(3);
4. Usdin, S. BioCentury
20(47), A1-A7; Nov. 19, 2012
5. Cain, C. SciBX 5(46);
AND INSTITUTIONS MENTIONED
Aeras, Rockville, Md.
Science, Technology and Research,
BGI, Shenzhen, China
Melinda Gates Foundation, Seattle,
The Centre for
Drug Research and Development,
Vancouver, British Columbia, Canada
plc (LSE:GSK; NYSE:GSK), London,
Corp., Waltham, Mass.
Medicines Initiative, Brussels,
National Institutes of Health, Bethesda, Md.
Sanofi (Euronext:SAN; NYSE:SNY), Paris, France
Vaccines Inc., St.